Expanded Access Policy
SENTYNL THERAPEUTICS, INC’S EXPANDED ACCESS POLICY FOR INVESTIGATIONAL DRUG CUTX-101 (COPPER HISTIDINATE) FOR TREATMENT OF MENKES DISEASE IS AVAILABLE HERE
SENTYNL THERAPEUTICS, INC’S EXPANDED ACCESS POLICY FOR INVESTIGATIONAL DRUG CUTX-101 (COPPER HISTIDINATE) FOR TREATMENT OF MENKES DISEASE IS AVAILABLE HERE